Nasdaq · Healthcare
Phathom Pharmaceuticals, Inc. (PHAT)
As-reported financials and recent SEC filings for Phathom Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$175.1M
Net income
$-221.2M
Net margin
-126.3%
Diluted EPS
$-3.03
ROE
50.5%
P/E (TTM)
—
Market cap
—
Debt / equity
-0.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $175.1M | $55.3M | $682,000 | $0 | — |
| Gross profit | $152.5M | $47.3M | $515,000 | — | — |
| Operating income | $-160.0M | $-277.5M | $-167.3M | $-172.4M | $-135.1M |
| Net income | $-221.2M | $-334.3M | $-201.6M | $-197.7M | $-143.9M |
| Diluted EPS | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-23
View on EDGAR →42026-05-27
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →Largest Healthcare peers
Go deeper on PHAT
Search Phathom Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.